Newsletter
| Promoter: | Penny Stock General | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| LPTN | No compensation | UNKNOWN |
| Max Profit: 2.67 % | Gain at close: -3.46 % | |
| *We think that this promoter is a part of a group of promoters. | ||
 |
|
Lpath Inc (LPTN) Traders, As promised, get LPTN on your screen now. We think it could run big today.
LPTN has been consolidating in a tight range for the past couple months, and we think it breakout of this range... in a big way. The chart setup is eerily similar to that of NYMX back at the start of this year, before it went on a monster run from around $0.40 all the way to $2. Except LPTN could be even bigger. Why?
Because LPTN has a much smaller market cap of only $5m and a tiny float of just $3.5m. And LPTN has over $12m cash on its books!!! That's more than 2x its market cap. That's practically unheard of. With yesterday's closing price of just $0.275, we think LPTN could double, even triple, in the coming days. And if it could run to $1, that's a 260% gain. And a "gap fill" back to $1.60ish would be almost a 500% gain. LPTN is also very liquid which means entering and exiting trades should be relatively easy. San Diego-based Lpath, Inc. (LPTN) is the category leader in lipid-targeted therapeutics. The company's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind and inhibit bioactive lipids that contribute to disease. Lpath annonced recently they will restructure its workforce and conduct a strategic evaluation of its research and development programs in order to conserve working capital and focus its resources on those programs deemed most likely to create value in the near term. The company expects that the reduction in workforce together with planned reductions or delays in other expenditures will decrease annualized cash expenditures significantly. With these planned spending reductions, Lpath estimates that its available cash and committed funding should be sufficient to fund the company's drug discovery and development activities through June 30, 2016. In addition to iSONEP, Lpath has three drug candidates in its pipeline. The status and plans for these drug candidates are summarized as follows: Lpath completed a Phase 2a clinical trial of ASONEP in renal cell carcinoma. While that study did not meet its primary endpoint, there were encouraging signals of activity, and Lpath is currently exploring additional indications for ASONEP. Please get LPTN on your screen now. This could run big today and in the coming days, but make sure you use proper risk management and be careful chasing any big gap ups at the open. The Team
www.PennyStockGeneral.com
Click Below to Join Our Social Media Networks
   |
|
---------------------------------------------------------------------------------------------------- DISCLAIMER ------------------------------------------------------------------------------------------------------
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Before buying or selling any pick featured in this newsletter you must read our full disclaimer can be read here Pennystockgeneral.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever.
The disclaimer is to be read and fully understood before using our site, or joining our email list. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead Pennystockgeneral.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Pennystockgeneral.com does not offer such advice or analysis, and Pennystockgeneral .com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, Pennystockgeneral.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, Pennystockgeneral .com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents have not completed any due diligence or research on the companies advertised herein and disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. Pennystockgeneral.com is not responsible for any claims made by the companies advertised herein. Pennystockgeneral.com may receive compensation and its employees and affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in Pennystockgeneral.com statements and opinions and such statements and opinions cannot be considered independent. Pennystockgeneral.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, Pennystockgeneral .com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. Pennystockgeneral.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the companies profile.
Pennystockgeneral.com has not been compensated for this profile. Pennystockgeneral.com may on occasion accept compensation in restricted or free-trading shares for it's marketing services of the company being profiled, and the third party that might have compensated Pennystockgeneral.com may hold free-trading shares of the company being profiled and could very well be selling shares of the companies stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. If Pennystockgeneral.com ever accepts compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services.
|
244 5th Ave, New York, NY 10001